Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso
Burkina Faso: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage was 91.0% in 2024. ▼ Falling
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso, 2014–2024
Source: WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data. Measured in %.
Analysis
The most recent figure for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso is 91.0%, measured in 2024. That is the highest value across all 11 years on record.
Compared with earlier readings it is unchanged over ten years.
Over the whole period, pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso peaked at 91.0% in 2014 and was at its lowest, 66.0%, in 2021.
That places Burkina Faso 52nd out of 146 countries with data for 2024, putting it in the middle of the range.
The long-run direction has been consistently falling across the 11 years of available data.
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso, year by year
| Year | % | Change |
|---|---|---|
| 2014 | 91.0% | — |
| 2015 | 91.0% | +0.0% |
| 2016 | 91.0% | +0.0% |
| 2017 | 91.0% | +0.0% |
| 2018 | 91.0% | +0.0% |
| 2019 | 91.0% | +0.0% |
| 2020 | 91.0% | +0.0% |
| 2021 | 66.0% | -27.5% |
| 2022 | 91.0% | +37.9% |
| 2023 | 91.0% | +0.0% |
| 2024 | 91.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 91.0% | 91.0% | 91.0% | 6 |
| 2020s | 86.0% | 66.0% | 91.0% | 5 |
Countries ranked near Burkina Faso
More health data for Burkina Faso
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.8925 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,142 deaths per 1,000 people (2090)
- Number of infants who die before age 1 13,085 deaths (2100)
- Population ages 15-19, male, annual growth rate 3.41 % change on previous year (2025)
- Population ages 15-19, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 15-19, male, per capita 0.0585 units per person (2025)
- Population ages 20-24, female, annual growth rate 3.24 % change on previous year (2025)
- Population ages 20-24, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 20-24, female, per capita 0.0467 units per person (2025)
Frequently asked questions
- What is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso?
- Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Burkina Faso was 91.0% in 2024, according to WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data.
- What is the highest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Burkina Faso?
- The highest recorded value was 91.0% in 2014.
- What is the lowest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Burkina Faso?
- The lowest recorded value was 66.0% in 2021.
- How does Burkina Faso rank for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Burkina Faso ranks 52nd out of 146 countries with data for 2024.
- Is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage rising or falling in Burkina Faso?
- Over the last ten years it is unchanged. The long-run trend across the full record is falling.
- Where does this Burkina Faso data come from?
- The figures come from WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as part of Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 11 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.